Eclectic Associates Inc. ADV Sells 139 Shares of Danaher Co. (NYSE:DHR)

Eclectic Associates Inc. ADV cut its stake in shares of Danaher Co. (NYSE:DHR) by 13.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 887 shares of the conglomerate’s stock after selling 139 shares during the quarter. Eclectic Associates Inc. ADV’s holdings in Danaher were worth $247,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of DHR. Tsfg LLC boosted its stake in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher during the second quarter worth $25,000. nVerses Capital LLC acquired a new position in Danaher during the second quarter worth $25,000. Redmont Wealth Advisors LLC acquired a new position in Danaher during the first quarter worth $30,000. Finally, Richardson Financial Services Inc. acquired a new position in Danaher during the fourth quarter worth $42,000. 79.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on DHR shares. Stephens started coverage on shares of Danaher in a report on Tuesday. They set an “overweight” rating and a $315.00 price objective on the stock. TD Cowen increased their target price on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Leerink Partners increased their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. The Goldman Sachs Group increased their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Finally, Stifel Nicolaus increased their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Danaher Stock Performance

NYSE:DHR traded down $0.49 on Friday, reaching $270.03. 1,132,669 shares of the company’s stock were exchanged, compared to its average volume of 2,759,666. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The firm has a market cap of $200.01 billion, a price-to-earnings ratio of 45.77, a P/E/G ratio of 4.55 and a beta of 0.83. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The stock has a fifty day simple moving average of $271.07 and a 200-day simple moving average of $258.56.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter last year, the business earned $2.05 earnings per share. As a group, sell-side analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Insider Activity

In other news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.